Survival of patients newly diagnosed with mayo stage iiia/iiib cardiac light chain amyloidosis on a bortezomib- or daratumumab-based therapy by isotype: results from a single site retrospective study

Clicks: 6
ID: 323521
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #48 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Light chain amyloidosis (AL) is a rare hematologic disorder. In AL, abnormal light chains from a clonal plasma cell dyscrasia (PCD) produce toxic amyloid fibrils that cause systemic organ dysfunction, thus high morbidity and mortality. AL is managed with anti-PCD therapies aiming to decrease the production of light chains and subsequent fibril deposition. Recommended first-line therapy includes cyclophosphamide-bortezomib-dexamethasone (CyBorD) with/without daratumumab. Patients with advanced AL, as defined by cardiac biomarkers per the European modified Mayo 2004 stage, are at high risk of death. Little is known about current patient outcomes by light chain isotype (kappa, lambda). The objective of this analysis was to assess overall survival of newly diagnosed, previously untreated AL patients with advanced cardiac stage initiating bortezomib- or daratumumab-based regimens in a single site in Greece. Methods This retrospective analysis included newly diagnosed adult patients with Mayo stage IIIa/IIIb AL who initiated on therapy ("index date") between 2018-2024 at our university. Patients receiving stem cell transplant, other amyloidosis forms, or in a clinical trial were excluded. The primary outcome of all-cause mortality was measured using Kaplan-Meier survival methods to generate survival probability as well as time to death, which were assessed in the overall population, and stratified by Mayo stage and isotype. Results A total of 104 patients met eligibility criteria, of which the majority were male (N=60; 57%) and a mean age of 67.8 years (SD=9.9); 54% (N=56) and 46% (N=48) were classified as European modified Mayo stage IIIa and IIIb, respectively. 29 (28%) and 75 (72%) of patients were identified as kappa and lambda isotype, respectively. The most common index treatment regimen was CyBorD (N=43; 41%), followed by CyBorD+daratumumab (N=32; 31%) and daratumumab monotherapy (N=27; 28%). Patients had follow-up for minimum of 2 weeks to a maximum of 362 weeks post-index. At 12 months post-index, the overall mortality was 37% with a mean time-to-death of 19.6 (SD=12.8) weeks. When stratified by isotype, 12-month mortality for the kappa and lambda overall patient population were 42% and 37%, respectively. When further stratified by stage, 12-month mortality for the kappa/lambda patients were 20%/22% (IIIa) & 64%/50% (IIIb), respectively. Discussion: This analysis assessed the survival among newly diagnosed AL patients with advanced disease who started on anti-PCD therapy, overall and when stratified by isotype in a single site database analysis. Mortality over the follow-up period varied depending on severity of disease and isotype, with higher mortality seen among kappa Mayo stage IIIb patients. High rates of mortality within certain patient categories underscore a significant unmet need that remains despite advances in treatment paradigms.
Reference Key
openalex_W7172299949 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J Catini, J Thompson, M Kalogeropoulou, K M Kontouli, J Zhou, E S Swenson, F Theodorakakou, M A Dimopoulos, E Kastritis
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.162
URL
https://doi.org/10.1093/eurheartjsupp/suag097.162
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.